Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, and breast cancer risk: observational and Mendelian randomization analyses with ∼430 000 women

What Was Tested

The paper reports a study of IGF-1 LR3, published as an observational study.

Epidemiological evidence supports a positive association between circulating insulin-like growth factor-1 (IGF-1) concentrations and breast cancer risk, but both the magnitude and causality of this relationship are uncertain.

The researchers conducted observational analyses with adjustment for regression dilution bias, and Mendelian randomization (MR) analyses allowed for causal inference.

Who Took Part

The study group was 206 women.

PubMed tags the participants as women only.

The researchers investigated the associations between circulating IGF-1 concentrations and incident breast cancer risk in 206 263 women in the UK Biobank.

HRs were corrected for regression dilution using repeat IGF-1 measures available in a subsample of 6711 women.

What Was Measured

The subject headings attached to it are Breast Neoplasms, Case-Control Studies, Insulin-Like Growth Factor Binding Protein 3, Insulin-Like Growth Factor I, Mendelian Randomization Analysis and Risk Factors.

The authors tagged it with the keywords breast cancer, insulin-like growth factor-1 (IGF-1), insulin-like growth factor-binding protein-3 (IGFBP-3) and observational.

What This Means in Plain Language

This is an observational study of IGF-1 LR3 in 206 women.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2020 (Annals of oncology : official journal of the European Society for Medical Oncology), a journal based in England.

More context: the IGF-1 LR3 compound page, all human trials.